| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers C > Headlines for Citigroup Inc. > News item |
Primary action thins; Citigroup subordinated notes mixed; Teva stronger; credit spreads firm
By Cristal Cody
Eureka Springs, Ark., July 20 – Investment-grade primary action stayed fairly quiet over Wednesday’s session.
About $23 billion of bonds have priced so far in the week with the bulk of issuance, including Teva Pharmaceutical Finance Netherlands III BV’s $15 billion six-part notes offering, coming on Monday.
Teva’s senior notes (Baa2/BBB/), which were brought to market to help finance its acquisition of the generics business of Allergan plc, traded about 10 basis points to 40 bps better than issuance earlier in the session.
Citigroup Inc.’s subordinated notes (Baa3/BBB/A-) traded flat to wider over the day.
The Markit CDX North American Investment Grade index closed on Wednesday 2 bps tighter at a spread of 70 bps.
Citi mixed
Citigroup’s 4.6% subordinated notes due 2026 headed out at 231 bps bid on Wednesday, about 6 bps softer since Monday, according to a market source.
Citigroup sold $1.5 billion of the notes on March 1 at a spread of Treasuries plus 280 bps.
The company’s new 4.125% subordinated notes due 2028 were flat at 255 bps offered in secondary trading earlier in the day.
Citigroup sold $1.5 billion of the notes on Monday at a spread of 258 bps over Treasuries.
The financial services company is based in New York.
Teva stronger
Teva Pharmaceutical Finance’s notes, which are guaranteed by Teva Pharmaceutical Industries Ltd., were stronger across the two- to 30-year maturities in secondary trading earlier on Wednesday, a market source said.
Teva’s 1.4% notes due 2018 were quoted at 61 bps offered. The company sold $1.5 billion of the notes on Monday at Treasuries plus 75 bps.
Teva’s 4.1% notes due 2046 were 12 bps tighter in the secondary market at 173 bps offered. The company priced $2 billion of the long bonds in Monday’s offering at 185 bps plus Treasuries.
The pharmaceutical company is based in Jerusalem.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.